Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime

Transplantation

Volumn 87, Issue 4, 2009, Pages 538-541

  Moro López, Jose A ^a,b,c   Almenar, Luis ^a   Martínez Dolz, Luis ^a   Sánchez Lázaro, Ignacio ^a   Agüero, Jaime ^a   Buendía, Francisco ^a   Ortiz, Víctor ^a   Salvador, Antonio ^a  

^a Heart Failure and Transplant Unit   (Spain)

^b Research Foundation   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Cardiac transplantation; Proliferation signal inhibitors; Renal failure

Indexed keywords

CREATININE; CYCLOSPORIN; EVEROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; IMMUNOLOGY; KIDNEY DISEASE; POSTOPERATIVE COMPLICATION; SMOKING;

DIABETES MELLITUS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; SMOKING;

EID: 65649125950     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819452ce     Document Type: Article

References (27)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115.
2. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 2007; 26: 769.
3. Alam A, Badovinac K, Ivis F, et al. The outcome of heart transplant recipients following the development of end-stage renal disease: Analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007; 7: 461.
4. Taylor DO, Edwards LB, Boucek MM, et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25: 869.
5. Satchithananda DK, Parameshwar J, Sharples L, et al. The incidence of end-stage renal failure in 17 years of heart transplantation: A single center experience. J Heart Lung Transplant 2002; 21: 651.
6. van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: A case-control study. Nephrol Dial Transplant 1998; 13: 2322.
7. Lidenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: Part II: Immunosuppressive drugs. Circulation 2004; 110: 3858.
8. Moro J, Almenar L, Martínez-Dolz L, et al. mTOR inhibitors: Do they help preserve renal function? Transplant Proc 2007; 39: 2135.
9. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26: 250.
10. Ruiz JC, Sánchez A, Rengel M, et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: Preliminary results of the EVERODATA registry. Transplant Proc 2007; 39: 2157.
11. ZuckermannA, ManitoN,EpaillyE,et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141.
12. Jabary NS, Martín D,Muñoz MF,et al. Serum creatinine and creatinine clearance to estimate renal function in essential hypertension. Nefrologia 2006; 26: 64.
13. Gustafsson F, Ross HJ, Delgado MS, et al. Sirolimus-based immuno-suppression after cardiac transplantation: Predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007; 26: 998.
14. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2: S45.
15. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
16. Klauke B, Wirth A, Zittermann A, et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant 2008; 27: 741.
17. Lyster H, Panicker G, Leaver N, et al. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004; 36: 3167.
18. Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 2129.
19. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
20. Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005; 24: 1863.
21. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540.
22. Moro J, Almenar L, Martínez-Dolz L, et al. mTOR inhibitors and their secondary effects in cardiac transplant recipients: A descriptive study. Transplant Proc 2007; 39: 2365.
23. Kahan BD. Sirolimus: A ten-year perspective. Transplant Proc 2004; 36: 71.
24. Barraclough K, Menahem SA, Bailey M, et al. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant 2006; 25: 1431.
25. Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663.
26. Ejerblad E, Fored CM, Lindblad P, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol 2004; 15: 2178.
27. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria. Transpl Int 2008; 21: 152.